Form 8-K - Current report:
SEC Accession No. 0001104659-22-028673
Filing Date
2022-03-01
Accepted
2022-03-01 16:10:46
Documents
14
Period of Report
2022-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm227931d1_8k.htm   iXBRL 8-K 26134
2 EXHIBIT 99.1 tm227931d1_ex99-1.htm EX-99.1 85741
6 GRAPHIC tm227931d1_ex99-1img001.jpg GRAPHIC 2288
  Complete submission text file 0001104659-22-028673.txt   302053

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rigl-20220301.xsd EX-101.SCH 3024
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rigl-20220301_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rigl-20220301_pre.xml EX-101.PRE 22589
8 EXTRACTED XBRL INSTANCE DOCUMENT tm227931d1_8k_htm.xml XML 3506
Mailing Address 1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO CA 94080
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

EIN.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29889 | Film No.: 22698072
SIC: 2834 Pharmaceutical Preparations